Early stem cell transplantation for chronic lymphocytic leukaemia:: a chance for cure?

被引:41
作者
Dreger, P
von Neuhoff, N
Kuse, R
Sonnen, R
Glass, B
Uharek, L
Schoch, R
Löffler, H
Schmitz, N
机构
[1] Univ Kiel, Dept Med 2, D-24116 Kiel, Germany
[2] Allgemeines Krankenhaus St Georg, Dept Hematol, Hamburg, Germany
关键词
chronic lymphocytic leukaemia; therapy; stem cell transplantation; polymerase chain reaction;
D O I
10.1038/bjc.1998.381
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
B-cell chronic lymphocytic leukaemia (CLL) cannot be cured by conventional therapy. To improve the prognosis of patients with CLL, we have designed a sequential treatment strategy that comprises intensive chemotherapy for mobilization of peripheral blood progenitor cells (PBPCs) and induction of minimal disease, followed by high-dose radiochemotherapy with stem cell reinfusion and post-transplant molecular monitoring by polymerase chain reaction (PCR) amplification of the complementary determining region III (CDRIII) gene. In a prospective study, we have evaluated this protocol in 18 patients with CLL, also including early stages of the disease. The median age was 49 (29-61) years; Binet stages were A, six; B, nine; and C, three. Adverse prognostic factors [high lymphocyte count and/or diffuse bone marrow (BM) infiltration] were present in 16 out of 18 patients. All patients showed a clone-specific molecular marker as demonstrated by PCR amplification of CDRIII rearrangements. For stem cell mobilization and reduction of tumour load, one to two cycles of Dexa-BEAM chemotherapy were administered, resulting in minimal disease (circulating lymphoma cells <1 x 10(9) l(-1); BM infiltration <20%; lymphomas <2 cm) in 16 out of 18 patients, including four patients who already had minimal disease before Dexa-BEAM. Stem cell harvesting was successful in 14 patients. All grafts [three BM, 11 peripheral blood (PB)] were purged from leukaemic cells using immunomagnetic methods. Thirteen patients having achieved minimal disease were reinfused with purged autologous stem cells (ASC) after preparation with total body irradiation and cyclophosphamide. Engraftment was delayed in patients receiving BM (n = 3) but prompt [neutrophils >0.5 x 10(9) l(-1) after 10 (9-13) days, platelets >20 x 10(9) l(-1) after 11 (9-214) days] in patients restored with PBPCs (n = 10). Procedure-related deaths did not occur. Although the results of CDRIII PCR suggest persistence or recurrence of the leukaemic clone in at least three cases, to date only one patient has relapsed, whereas all others survive without clinical evidence of disease with a maximum follow-up of 48 months. We conclude that sequential high-dose therapy using Dexa-BEAM and autologous stem cell transplantation is a safe and highly effective treatment for patients with CLL. However, a longer follow-up is needed to assess whether definite cures can be achieved using this strategy.
引用
收藏
页码:2291 / 2297
页数:7
相关论文
共 34 条
[1]  
BASTION Y, 1992, BONE MARROW TRANSPL, V10, P467
[2]   INTENSIVE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN 60 PATIENTS WITH POOR-PROGNOSIS FOLLICULAR LYMPHOMA [J].
BASTION, Y ;
BRICE, P ;
HAIOUN, C ;
SONET, A ;
SALLES, G ;
MAROLLEAU, JP ;
ESPINOUSE, D ;
REYES, F ;
GISSELBRECHT, C ;
COIFFIER, B .
BLOOD, 1995, 86 (08) :3257-3262
[3]   POSITIVELY SELECTED AUTOLOGOUS BLOOD CD34+ CELLS AND UNSEPARATED PERIPHERAL-BLOOD PROGENITOR CELLS MEDIATE IDENTICAL HEMATOPOIETIC ENGRAFTMENT AFTER HIGH-DOSE VP16, IFOSFAMIDE, CARBOPLATIN, AND EPIRUBICIN [J].
BRUGGER, W ;
HENSCHLER, R ;
HEIMFELD, S ;
BERENSON, RJ ;
MERTELSMANN, R ;
KANZ, L .
BLOOD, 1994, 84 (05) :1421-1426
[4]   P53 GENE DELETION PREDICTS FOR POOR SURVIVAL AND NONRESPONSE TO THERAPY WITH PURINE ANALOGS IN CHRONIC B-CELL LEUKEMIAS [J].
DOHNER, H ;
FISCHER, K ;
BENTZ, M ;
HANSEN, K ;
BENNER, A ;
CABOT, G ;
DIEHL, D ;
SCHLENK, R ;
COY, J ;
STILGENBAUER, S ;
VOLKMANN, M ;
GALLE, PR ;
POUSTKA, A ;
HUNSTEIN, W ;
LICHTER, P .
BLOOD, 1995, 85 (06) :1580-1589
[5]   11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis [J].
Dohner, H ;
Stilgenbauer, S ;
James, MR ;
Benner, A ;
Weilguni, T ;
Bentz, M ;
Fischer, K ;
Hunstein, W ;
Lichter, P .
BLOOD, 1997, 89 (07) :2516-2522
[6]  
Dreger P, 1997, LEUKEMIA, V11, pS42
[7]  
DREGER P, 1995, BONE MARROW TRANSPL, V16, P627
[8]   EFFECTIVE MOBILIZATION OF PERIPHERAL-BLOOD PROGENITOR CELLS WITH DEXA-BEAM AND G-CSF - TIMING OF HARVESTING AND COMPOSITION OF THE LEUKAPHERESIS PRODUCT [J].
DREGER, P ;
MARQUARDT, P ;
HAFERLACH, T ;
JACOBS, S ;
MULVERSTEDT, T ;
ECKSTEIN, V ;
SUTTORP, M ;
LOFFLER, H ;
MULLERRUCHHOLTZ, W ;
SCHMITZ, N .
BRITISH JOURNAL OF CANCER, 1993, 68 (05) :950-957
[9]   AUTOLOGOUS PROGENITOR-CELL TRANSPLANTATION - PRIOR EXPOSURE TO STEM CELL-TOXIC DRUGS DETERMINES YIELD AND ENGRAFTMENT OF PERIPHERAL-BLOOD PROGENITOR-CELL BUT NOT OF BONE-MARROW GRAFTS [J].
DREGER, P ;
KLOSS, M ;
PETERSEN, B ;
HAFERLACH, T ;
LOFFLER, H ;
LOEFFLER, M ;
SCHMITZ, N .
BLOOD, 1995, 86 (10) :3970-3978
[10]   PROSPECTIVE-STUDY OF THE OCCURRENCE OF MONOCLONAL GAMMOPATHIES FOLLOWING BONE-MARROW TRANSPLANTATION IN YOUNG-CHILDREN [J].
FISCHER, AM ;
SIMON, F ;
LEDEIST, F ;
BLANCHE, S ;
GRISCELLI, C ;
FISCHER, A .
TRANSPLANTATION, 1990, 49 (04) :731-735